IntegenX

Thermo Fisher said that IntegenX complements and enhances its existing human identification product portfolio.

The RapidHit ID instrument.

The new platform is smaller and less expensive than the company's first-generation forensic DNA platform, processing a single DNA sample in around 70 minutes.

Peter Vallone

Vallone recently authored a review of the field, noting that fully integrated rapid systems have special advantages.

Squad Car Profiling

Law enforcement agencies are enthusiastic about the potential for rapid DNA profiling, Mother Jones reports.

NEW YORK (GenomeWeb) – Human DNA identification firm IntegenX and Horizon Technology Finance said on Monday that IntegenX has secured a $10 million venture loan.

The University of Massachusetts has been awarded

NEW YORK (GenomeWeb) – Biometric solutions firm Morpho will market IntegenX's RapidHit DNA analysis system to law enforcement and government agencies in certain countries as part of a deal announced today.

NEW YORK (GenomeWeb News) – Human DNA identification technology company IntegenX today said it has earned ISO 9001:2008 certification for its quality management system.

A week after announcing 2013 revenues of $1.3 million — more than double its 2012 revenues — WaferGen Biosystems this week set a lofty goal of more than $5 million for its top line in 2014

IntegenX said this week that it has met Federal Bureau of Investigation guidelines to upload directly to the National DNA Index System (NDIS) known arrestee and convicted offender DNA profiles, as well as casework known samples, generated with the company's RapidHIT Syste

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.